
Intuitive Surgical, Inc.
NASDAQ•ISRG
CEO: Dr. Gary S. Guthart Ph.D.
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2000-06-16
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Contact Information
Market Cap
$193.78B
P/E (TTM)
70.4
76.8
Dividend Yield
--
52W High
$616.00
52W Low
$425.00
52W Range
Rank31Top 15.1%
5.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$2.51B+22.91%
4-Quarter Trend
EPS
$1.98+24.53%
4-Quarter Trend
FCF
$735.60M+60.40%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Growth Strong Total revenue $7.20B for nine months, reflecting 21% growth versus prior period, driven by product sales.
Net Income Surges Net income attributable $2.06B for nine months, marking strong 26% increase compared to the prior year period.
Procedure Volume Rises da Vinci procedures reached 2.68M total for nine months, showing 18% volume increase across US and OUS.
Ion Adoption Accelerates Ion system placements totaled 153 units for nine months, reflecting 54% procedure volume growth year-to-date.
Risk Factors
Gross Margin Compression Gross profit margin fell to 65% for nine months, down from 67% last year due to cost pressures.
Tariff Cost Impact Tariffs increased Cost of Revenue by $37M for nine months ended September 2025, impacting profitability.
Litigation Exposure Unresolved Product liability lawsuits remain unresolved; management cannot estimate potential loss exceeding current accruals.
Macroeconomic Headwinds Persist Liquidity risks exist from inflation, elevated interest rates, and ongoing supply chain challenges globally.
Outlook
Da Vinci 5 System Launch Phased launch of next-generation da Vinci 5 system continues across OUS markets, driving ASP increase.
European Distribution Acquisition Pending acquisition of European distribution businesses requires upfront cash payment of approximately EUR 290M.
Capital Investment Planned Expect $625M to $675M capital expenditures for 2025, primarily funding facilities expansion and vertical integration.
R&D Investment Increasing Research and development expenses increased 13% year-to-date, expected to continue rising for platform initiatives.
Peer Comparison
Revenue (TTM)
BDX$21.84B
BAX$11.02B
ISRG$9.61B
Gross Margin (Latest Quarter)
ISRG66.4%
RMD61.5%
COO61.1%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ISRG | $193.78B | 70.4 | 16.1% | 0.0% |
| BDX | $57.59B | 34.3 | 6.6% | 34.7% |
| RMD | $36.97B | 25.7 | 25.1% | 10.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.2%
Moderate Growth
4Q Net Income CAGR
0.9%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Jan 22, 2026
EPS:$2.25
|Revenue:$2.72B
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 22, 2025|Revenue: $2.51B+22.9%|EPS: $1.98+24.5%MeetForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 23, 2025|Revenue: $2.44B+21.4%|EPS: $1.84+24.3%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: Apr 23, 2025|Revenue: $2.25B+19.2%|EPS: $1.95+26.6%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Jan 31, 2025|Revenue: $8.35B+17.2%|EPS: $6.54+27.7%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 18, 2024|Revenue: $2.04B+16.9%|EPS: $1.59+34.7%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 19, 2024|Revenue: $2.01B+14.5%|EPS: $1.48+23.3%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: Apr 19, 2024|Revenue: $1.89B+11.5%|EPS: $1.54+52.5%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Jan 31, 2024|Revenue: $7.12B+14.5%|EPS: $5.12+37.6%Beat